Establishment of cancer immunotherapy in vitro model

Main Article Content

Jana Veprkova
Andrej Besse
Lenka Sedlarikova
Lenka Besse

Abstract

T cells play a central role in cancer immunotherapy, yet the lack of standardized in vitro models limits the reproducibility and translational potential of immune-cancer cell interaction studies. Existing models often lack reproducibility due to variability in experimental conditions, immune cell sources, and functional assays.


To address this gap, we established a robust and reproducible in vitro co-culture model, which serves to evaluate efficacy of the immune cell-based cytotoxicity using peripheral blood mononuclear cells (PBMCs) and multiple cancer cell lines. Healthy donor PBMCs supplemented with IL-2 are co-cultured with (educated) or without (naïve) cancer cell lines for two weeks. The model cell lines are equipped with a luciferase reporter, enabling real-time quantification of immune-mediated killing through assessment of luminescence intensity.


Single-cell RNA sequencing analysis of educated vs. naïve immune cells revealed favorable expansion and differentiation of CD8+ cytotoxic T cells while compromised expansion of CD4+ helper T cells. Moreover, the strong upregulation of Granzyme and Perforin expression in CD8+ T cells is indicative of cytolytic function.


Initially validated using the pancreatic cancer cell line PANC-1, the model was further applied to lung cancer (A549) and multiple myeloma (AMO-1), demonstrating its versatility across malignancies. Despite the MHC non-restricted nature of PBMC cytotoxicity—due to lack of HLA compatibility—PBMCs exhibited a 40-80% increase in selective killing of the cancer cell line to which they were educated, compared to non-educated conditions.


While the use of healthy donor PBMCs poses a potential limitation in clinical settings due to the risk of graft-versus-host disease (GVHD), this model provides a highly adaptable and reproducible in vitro platform for studying T-cell mediated anti-cancer responses and optimizing immunotherapeutic approaches.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Veprkova J, Besse A, Sedlarikova L, Besse L. Establishment of cancer immunotherapy in vitro model. SEE J Immunol [Internet]. 2025 Mar. 25 [cited 2026 Nov. 17];8(CITIM):079. Available from: https://seejim.eu/index.php/seejim/article/view/6142
Section
Posters